Olympus Corporation (OCPNF) fair value: what the stock is really worth
As of Oct 14, 2026: fair value (intrinsic value) of Olympus Corporation stock $6.84, price $11.20, that is 38.9% below the price, quality 58 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range $6.62 – $24.20 · fair‑value band $4.79 – $8.89 · the $11.20 price screens above the $6.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 1, 2026.
Follow Olympus in your weekly email
Every Wednesday you see whether Olympus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, "Gastrointestinal Solutions and Surgical & Interventional Solutions.
Show moreShow less
The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products.
It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat.
The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
Stock analysis
Olympus Corporation (OCPNF) currently trades at $11.20, while our model-based Fair Value estimate is $6.84, 38.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $11.15 per share, and 5 of the 24 models we run sit above the $11.20 price.
Bear case: the Dividend Discount group reads lowest at $1.85, and 19 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: $4.79 (bear) to $8.89 (bull), the price of $11.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Olympus Corporation reported revenue of ¥1.0T in FY2026 versus ¥869B in FY2022, a compound +4.0%/yr. Reported net income was ¥68.6B in FY2026, compounding −12.3%/yr from FY2022.
Key figures
Market cap $12.5B Large · P/E ratio 27.3 · P/S ratio 1.84 · EPS (TTM) $0.4100 · Dividend yield 1.7% · Net margin 6.7% · Return on equity 10.6% · Return on assets (EBIT) 11.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (medium confidence).
What moves the price
The share trades about 20% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −39%, OCPNF screens richer than that median.
Fair Value models
Bear$4.79Fair Value $6.84Bull$8.89
Price $11.20 · Downside -38.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.2438 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Start year 2021 (pandemic). Over 10 years: +2.4% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.8%
Dividend (yield on the price)1.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.9% vs 4.8%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 15%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about +17.1% a year for the price and +1.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (75 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
AI conclusion: Modest scale in medical devices offers a focused pure-play profile after the divestiture, yet this is offset by limited pricing evidence and past governance issues.
Main risk: Ongoing FDA import alerts and warning letters over quality system violations could restrict or halt shipments of key Olympus endoscopes and related devices from Japan into the major US market.
Bull case: Olympus could resolve the FDA quality issues through remediation and leverage its installed base plus investments in AI-powered and robotic endoscopy to maintain leadership in minimally invasive procedures.
Bear case: Prolonged regulatory restrictions combined with faster adoption of single-use alternatives from competitors could significantly reduce Olympus access to the US market and erode its position in reusable endoscopy.
Olympus is selling its industrial microscope subsidiary to focus exclusively on medical technology. This move sharpens its profile as a pure-play MedTech company centered on endoscopes and related devices. Our models currently see the stock as overvalued. Will the streamlined medical focus unlock stronger growth or expose limits in its core operations?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 322 stocks
Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−38.9% · Below median
Profitability
Return on equity (12 months)10.6% · Above median
Return on assets4.4% · Above median
Net margin (12 months)7.5% · Above median
Operating margin (12 months)12.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)16.4% · Above median
Dividend yield (12 months)1.7% · Below median
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)27.3× · Pricier than median
P/B2.41× · Pricier than median
P/S (12 months)1.89× · Cheaper than median
Price / free cash flow43.5× · Priciest 25%
EV/EBITDA8.9× · Cheapest 25%
PEG3.61× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 8
FUTURE (revenue growth)82· sector 36
PAST (return on equity)42· sector 16
HEALTH (low debt)90· sector 98
DIVIDEND (yield)34· sector 36
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Olympus Corporation Fair Value". https://www.fairvalue-calculator.com/stock/OCPNF
Frequently asked questions
Is Olympus Corporation (OCPNF) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of $6.84 versus the last price from Oct 14, 2026 of $11.20, about 39% lower (overvalued).
What is the fair value of OCPNF?
Our model-based fair value for Olympus Corporation is $6.84 (as of Nov 1, 2026), built from audited fundamentals. Last price (from Oct 14, 2026): $11.20.
What is the quality score of OCPNF?
Olympus Corporation has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Olympus Corporation (OCPNF)?
Our model-based price target is the fair value of $6.84 (as of Nov 1, 2026) from 24 valuation models. Cautious scenario $4.79, optimistic scenario $8.89. It is a calculation from audited fundamentals, not an analyst target.
What is the Olympus Corporation stock forecast for 2026?
Our models put fair value at $6.84, about 39% lower versus the last price from Oct 14, 2026 of $11.20 (overvalued). Cautious scenario $4.79, optimistic scenario $8.89. The calculation is refreshed regularly with new filings.
What is the revenue of Olympus Corporation (OCPNF)?
Olympus Corporation reported trailing-twelve-month revenue of about ¥1.0T (latest available figure, as of Nov 1, 2026).
Does Olympus Corporation pay a dividend?
Olympus Corporation currently shows a dividend yield of 1.69% relative to its recent price (as of Nov 1, 2026).
What growth is priced into Olympus Corporation (OCPNF)?
For today's price to be fair in a discounted-cash-flow model, Olympus Corporation would have to grow free cash flow by +19.5 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.8 % per year. As of Nov 1, 2026.
What discount rate (WACC) does the fair value of OCPNF use?
Our models discount Olympus Corporation at 8.1 %: a base by market capitalisation (large), damped by beta 0.26, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Olympus Corporation that is +19.5 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Olympus Corporation (OCPNF) delivered so far?
Over the past 5 years revenue at Olympus Corporation grew +6.8 % a year. The price currently implies +19.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Olympus Corporation (OCPNF) growing?
The median revenue growth in the sector is +6.4 % a year. That is the yardstick for the growth priced into Olympus Corporation (+19.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Olympus Corporation (OCPNF)?
The free-cash-flow yield on the price is 2.30 %: that much free cash flow Olympus Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Olympus Corporation (OCPNF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Olympus Corporation it is $6.84 per share (as of Nov 1, 2026), against a price of $11.20. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Olympus Corporation stock overvalued or undervalued in 2026?
As of Nov 1, 2026, OCPNF trades above its calculated fair value: price $11.20, fair value $6.84, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OCPNF?
No. The price is what the market pays today ($11.20); the fair value is what the company's own numbers justify ($6.84). For Olympus Corporation the two are $4.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is Olympus Corporation worth?
The market values Olympus Corporation at about $12.5B (market capitalisation, as of Nov 1, 2026). Per share that is $11.20; our models calculate a fair value of $6.84 per share.
What do the bullish and bearish scenarios say about OCPNF?
Our models span a range for Olympus Corporation: cautious scenario $4.79, base $6.84, optimistic $8.89 per share (as of Nov 1, 2026, price $11.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OCPNF?
Olympus Corporation trades at a price-to-earnings ratio of 27.3 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $6.84 is built from several models across several years. Other multiples: PEG 3.6, P/B 2.4, P/S 1.9, EV/EBITDA 8.9.
What is the PEG ratio of OCPNF?
The PEG ratio of Olympus Corporation is 3.61 (P/E divided by earnings growth, as of Nov 1, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Olympus Corporation (OCPNF)?
Balance-sheet figures for Olympus Corporation (as of Nov 1, 2026): return on equity 10.6%, debt of 0.20 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is OCPNF from its 52-week high?
Olympus Corporation trades at $11.20, about 20% below its 52-week high of $14.00 and 40% above the low of $8.00 (as of Nov 2, 2026). Distance from the high says nothing about value: that is what the fair value of $6.84 is for.
Which stocks are comparable to Olympus Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Olympus Corporation stock attractive at the current price?
The data as of Nov 1, 2026: price $11.20, calculated fair value $6.84 (−39%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OCPNF calculated?
We run Olympus Corporation through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2 % above its aggregate fair value. Olympus Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Olympus Corporation (OCPNF)?
The latest price we hold is from Oct 14, 2026 and stands at $11.20. Our model-based fair value is $6.84, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Olympus Corporation right now?
The price sits above even our optimistic bull case ($8.89). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($4.79 to $8.89) leaves room in how you read the outcome.
Where does the earnings growth of Olympus Corporation (OCPNF) come from?
Earnings per share at Olympus Corporation grew +14.7 % a year from 2016 to 2026. Broken into its drivers: revenue per share +4.9 %, EBIT margin +3.2 %, tax rate +0.8 %, residual (interest, one-offs) +5.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Olympus Corporation
How large is the market capitalisation of Olympus Corporation (OCPNF)?
The market capitalisation of Olympus Corporation is $12.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Olympus Corporation (OCPNF)?
The price-to-sales ratio of Olympus Corporation is 1.84 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Olympus Corporation (OCPNF)?
Earnings per share at Olympus Corporation are $0.4100 (price ÷ EPS = P/E 27.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Olympus Corporation (OCPNF)?
The dividend yield of Olympus Corporation is 1.7% (payout 46.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Olympus Corporation (OCPNF)?
The net margin of Olympus Corporation is 6.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Olympus Corporation (OCPNF)?
The return on equity (ROE) of Olympus Corporation is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Olympus Corporation (OCPNF)?
On an EBIT basis the return on assets of Olympus Corporation is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Olympus Corporation (OCPNF)?
The operating margin of Olympus Corporation is 12.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Olympus Corporation (OCPNF)?
Revenue at Olympus Corporation is growing +16.4% versus a year earlier (3y avg +4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Olympus Corporation (OCPNF)?
Earnings per share at Olympus Corporation are growing +123% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Olympus Corporation (OCPNF) carry?
The net debt of Olympus Corporation is ¥51.9B (fiscal year 2026, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Olympus Corporation in the live analysis
One click puts Olympus Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 1, 2026